摘要
目的观察多西他赛联合泼尼松化疗方案对激素难治性前列腺癌的近期疗效和不良反应。方法采用多西他赛(75 mg/m^2)联合小剂量泼尼松(5 mg,2次/d)3周方案对14例51～78岁激素难治性前列腺癌患者进行3～8周期化疗,比较化疗前后总前列腺特异性抗原(T-PSA)、碱性磷酸酶、疼痛评分、骨及可测量病灶的变化等进行近期疗效评估,并了解本化疗方案的不良反应。结果每周期总剂量在100～140 mg,共治疗1～8周期不等。PSA 降低反应显效5例,有效3例,无效6例,总有效率为57.1%;6例 N_1患者中有2例淋巴结缩小,有1例显示淋巴结有增大,余无明显变化;骨扫描化疗后2例好转;化疗后疼痛评分减轻0～6分;Karnofsky 评分平均增加4%。化疗不良反应主要为骨髓抑制、脱发、乏力、甲床改变、静脉炎等。结论多西他赛联合泼尼松化疗方案可抑制激素难治性前列腺癌的进展,使 PSA 降低、淋巴结缩小、减轻疼痛、改善生活质量,化疗耐受性较好。
Objective To investigate the role and side effects of docetaxel and prednisone on treating hormone-refractory prostate cancer （ HRPC ）. Methods Docetaxel （75 mg/m^2 ） and prednisone （5mg, bid） were given to 14 patients, whose age range from 51 to 78 years old, of hormone-refractory prostate cancer for 3-8 cycles. Three-week is a chemotherapy cycle. Comparing the prostate specific antigen （PSA）, alkaline phosphatase （ALP）, pain score, Karnofsky performance status, bone scan, lymph node size before and after chemotherapy. Results 100-140 milligram docetaxel were given for each cycle, 1-8 cycles were experienced. The responses of PSA ： excellence-5 cases, utility-3 cases, uselessness-6 cases, PSA response ratio was 57. 1%. Among 6 N1 cases, lymph nodes diminished in 2 cases and enlarged in 1 case after chemotherapy. Bone scan has improved in 2 cases, and no differences in other cases. Pain scores were decreased from 0 to 6, and the average Karnofsky performance status was increased by 4% . The common adverse events were myelosuppression, alopecia, fatigue, nail changes, phlebitis. Conclusion Docetaxel plus prednisone for the treatment of HRPC can delay the progression of the disease, decrease the PSA value, diminish the lymph node, ease the pain, improve the quality of live, and the tolerance is quite
出处
《中华医学杂志》
CAS
CSCD
北大核心
2007年第24期1666-1668,共3页
National Medical Journal of China
关键词
前列腺肿瘤
药物疗法
联合
泼尼松
多西他赛
Prostatic neoplasms
Drug therapy, combination
Prednisone
Docetaxel
